Insider Buying: Dyne Therapeutics (NASDAQ:DYN) Director Acquires $33,880.00 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Brian Posner purchased 2,000 shares of the firm’s stock in a transaction on Monday, June 8th. The shares were purchased at an average price of $16.94 per share, for a total transaction of $33,880.00. Following the completion of the purchase, the director directly owned 24,500 shares of the company’s stock, valued at $415,030. This represents a 8.89% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link.

Dyne Therapeutics Stock Up 1.6%

NASDAQ:DYN opened at $17.95 on Friday. The company has a quick ratio of 19.92, a current ratio of 19.92 and a debt-to-equity ratio of 0.17. The stock’s fifty day moving average is $18.27 and its two-hundred day moving average is $18.18. Dyne Therapeutics, Inc. has a 52 week low of $8.06 and a 52 week high of $25.00. The stock has a market capitalization of $2.97 billion, a price-to-earnings ratio of -5.57 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.04. During the same period last year, the firm earned ($1.05) EPS. Research analysts anticipate that Dyne Therapeutics, Inc. will post -3 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Wall Street Zen upgraded Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Chardan Capital restated a “buy” rating and set a $38.00 price target on shares of Dyne Therapeutics in a research note on Monday, March 9th. Evercore set a $33.00 price target on Dyne Therapeutics in a research note on Friday, May 15th. Jefferies Financial Group reiterated a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, March 9th. Finally, HC Wainwright reduced their price objective on Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, March 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $35.00.

Institutional Trading of Dyne Therapeutics

Several hedge funds have recently modified their holdings of DYN. AQR Capital Management LLC acquired a new stake in shares of Dyne Therapeutics in the first quarter valued at $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Dyne Therapeutics by 5.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock valued at $597,000 after acquiring an additional 2,886 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Dyne Therapeutics by 58.2% in the first quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company’s stock valued at $10,407,000 after acquiring an additional 366,183 shares in the last quarter. Caxton Associates LLP acquired a new stake in shares of Dyne Therapeutics in the first quarter valued at $157,000. Finally, Creative Planning raised its stake in shares of Dyne Therapeutics by 23.8% in the second quarter. Creative Planning now owns 14,541 shares of the company’s stock valued at $138,000 after acquiring an additional 2,797 shares in the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.